Last reviewed: May 16, 2026
Last updated: May 16, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
ShedRx reviews often raise questions about compounding pharmacy oversight and credential verification. Understanding the difference between 503A and 503B compounding pathways is essential when evaluating any provider offering compounded medications, including GLP-1 therapies.
Patients considering compounded peptide medications deserve transparency about licensing, quality assurance, and regulatory pathways. PlexusDx prioritizes this clarity by exclusively partnering with licensed 503A compounding pharmacies, supporting informed decision-making with healthcare providers.
Understanding 503A Versus 503B Compounding Pathways
The FDA distinguishes between 503A and 503B compounding pharmacies based on regulatory oversight, patient relationship requirements, and supply chain transparency. A 503A pharmacy compounds medications for individual patients with a valid prescription from a licensed provider. This pathway includes state board oversight and direct patient accountability.
503B pharmacies operate as manufacturer-level facilities without state pharmacy board oversight and may prepare medications without a specific patient relationship. PlexusDx exclusively uses 503A compounding pharmacies, ensuring each compounded medication is prepared under direct provider supervision for identified patients.
Key Licensing and Oversight Distinctions in Compounding Pharmacy Models
Evaluating a compounding pharmacy requires understanding the regulatory framework supporting its operations. The table below outlines critical differences between 503A and 503B pathways that affect safety, transparency, and accountability.
| Compounding Pathway |
State Oversight |
Patient Relationship Required |
Transparency Requirements |
PlexusDx Model |
| 503A Pharmacy |
State board regulates and inspects |
Yes—direct prescriber-patient relationship |
High—individual patient accountability |
Exclusive partner pathway |
| 503B Facility |
FDA oversight only; no state board |
No—can distribute without patient relationship |
Limited—manufacturer-level operations |
Not used by PlexusDx |
| Unlicensed/Unregulated |
None |
None |
None |
Not applicable |
| International or Unverified |
Variable or absent |
Often absent |
Often minimal |
Not used by PlexusDx |
Verifying Credentials and Pharmacy Licensing Status
Before engaging with any compounding pharmacy, patients and providers should verify state pharmacy board licensing, inspect facility registrations, and confirm accreditation status. Most states maintain online searchable databases of licensed pharmacies. This verification step protects both clinical safety and legal accountability.
PlexusDx partners exclusively with 503A compounding pharmacies that maintain active state licensing and operate under direct pharmaceutical oversight. Each compounding facility has documented quality assurance protocols, sterility standards, and ongoing provider communication requirements built into the compounding and dispensing process.
Who This Regulatory Framework Protects and Why It Matters
Patients beginning compounded GLP-1 therapy—whether semaglutide, tirzepatide, or other peptide medications—benefit from 503A oversight because it ensures provider accountability, pharmaceutical consistency, and regulatory recourse if issues arise. This pathway is particularly important for individuals with complex medical histories or multiple concurrent medications.
Choosing a provider that exclusively uses 503A compounding pharmacies supports informed conversations with your healthcare team about medication sourcing, quality assurance, and personalized treatment adjustments. PlexusDx's commitment to 503A partnerships aligns with this principle of transparency and clinical governance.
How PlexusDx Supports a More Personalized Approach
PlexusDx genetic insights may help provide context for how individual peptide pathways function, supporting more informed conversations about compounding pharmacy choice and medication personalization. The Precision Peptide Genetic Test reveals predispositions in key GLP-1 and peptide-related genetic variants, including GIPR, GLP1R, FTO, and MC4R. These insights should be interpreted with a qualified healthcare provider.
Understanding your genetic predispositions in peptide pathways—revealed through the Precision Peptide Genetic Test ($99 add-on or $298 standalone)—can support a more personalized conversation with your provider about compounding options, dosing strategies, and medication selection. The test identifies predispositions, not exact medication response, and complements clinical evaluation.
When selecting a compounded medication provider, combining knowledge of 503A licensing standards with your personal genetic context can support a more comprehensive partnership with your healthcare team. PlexusDx integrates both regulatory transparency and precision genetic assessment to align treatment decisions with your individual physiology.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What does 503A licensing mean for a compounding pharmacy?
503A licensing indicates state board oversight, direct patient relationships, and accountability to a licensed pharmacist. This pathway ensures quality assurance, sterility standards, and regulatory compliance at the state level.
Why does PlexusDx exclusively use 503A compounding pharmacies?
503A partnerships ensure direct provider oversight, transparent sourcing, state regulation, and individual patient accountability. This aligns with PlexusDx's commitment to precision, safety, and clinical governance in compounded peptide medications.
How can I verify if a compounding pharmacy is licensed and legitimate?
Search your state pharmacy board's online database, request proof of state licensure, and confirm accreditation with organizations like the Pharmacy Compounding Accreditation Board. Ask about quality assurance protocols and provider communication procedures.
Are compounded medications from 503A pharmacies FDA-approved?
Compounded medications are not FDA-approved in the same way brand-name drugs are, but 503A compounding operates under FDA oversight and state pharmacy board regulation. Quality assurance and sterility standards are enforced through both pathways.
How do genetic predispositions relate to choosing a compounding pharmacy partner?
The Precision Peptide Genetic Test reveals predispositions in peptide pathways that may inform medication selection and dosing conversations with your provider. This information, combined with 503A pharmacy accountability, supports more personalized treatment planning.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
WeightWatchers Alternative: Precision GLP-1 Therapy and Genetic Context
Fella Health Review: Editorial Look at Business Model, Pricing